Pular para o conteúdo
Merck
Todas as fotos(1)

Documentos Principais

Visualizar Toda a Documentação

Y0000521

Nevirapine for peak identification

European Pharmacopoeia (EP) Reference Standard

Sinônimo(s):

Nevirapine, 11-Cyclopropyl-5,11-dihydro-4-methyl-6H-dipyrido[3,2-b:2′,3′-e][1,4]diazepin-6-one

Faça loginpara ver os preços organizacionais e de contrato
Todas as fotos(1)

About This Item

Fórmula empírica (Notação de Hill):
C15H14N4O
Número CAS:
129618-40-2
Peso molecular:
266.30
Número MDL:
MFCD00866928
Código UNSPSC:
41116107
ID de substância PubChem:
329831002
NACRES:
NA.24
Preço e disponibilidade não estão disponíveis no momento.

grau

pharmaceutical primary standard

família API

nevirapine

fabricante/nome comercial

EDQM

aplicação(ões)

pharmaceutical (small molecule)

Formato

neat

temperatura de armazenamento

2-8°C

cadeia de caracteres SMILES

CC1=CC=NC2=C1NC(C(C=CC=N3)=C3N2C4CC4)=O

InChI

1S/C15H14N4O/c1-9-6-8-17-14-12(9)18-15(20)11-3-2-7-16-13(11)19(14)10-4-5-10/h2-3,6-8,10H,4-5H2,1H3,(H,18,20)

chave InChI

NQDJXKOVJZTUJA-UHFFFAOYSA-N

Procurando produtos similares? Visita Guia de comparação de produtos

Categorias relacionadas

Descrição geral

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Aplicação

Nevirapine for peak identification EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Ações bioquímicas/fisiológicas

NNRTI (non-nucleoside reverse transcriptase inhibitor) of HIV-1
Nevirapine is an allosteric, non-nucleoside inhibitor of HIV reverse transcriptase (NNRTI). The Ki for inhibition of wild-type RT by Nevirapine is 200 nM.

Embalagem

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Outras notas

Sales restrictions may apply.

produto relacionado

Nº do produto
Descrição
Preços

Y0000520

Nevirapine (anhydrous), European Pharmacopoeia (EP) Reference Standard

Y0001499

Nevirapine hemihydrate, European Pharmacopoeia (EP) Reference Standard

1460703

Nevirapine anhydrous, United States Pharmacopeia (USP) Reference Standard

1460714

Nevirapine hemihydrate, United States Pharmacopeia (USP) Reference Standard

1460725

Nevirapine Related Compound A, United States Pharmacopeia (USP) Reference Standard

1460736

Nevirapine Related Compound B, United States Pharmacopeia (USP) Reference Standard

1460747

Nevirapine Related Compound C, United States Pharmacopeia (USP) Reference Standard

PHR1757

Nevirapine, Pharmaceutical Secondary Standard; Certified Reference Material

PHR1760

Nevirapine Related Compound A, Pharmaceutical Secondary Standard; Certified Reference Material

PHR1761

Nevirapine Related Compound B, Pharmaceutical Secondary Standard; Certified Reference Material

PHR1762

Nevirapine Related Compound C, Pharmaceutical Secondary Standard; Certified Reference Material

Código de classe de armazenamento

11 - Combustible Solids

Classe de risco de água (WGK)

WGK 2

Ponto de fulgor (°F)

Not applicable

Ponto de fulgor (°C)

Not applicable

Escolha uma das versões mais recentes:

Certificados de análise (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documentos section.

Se precisar de ajuda, entre em contato Atendimento ao cliente

Já possui este produto?

Encontre a documentação dos produtos que você adquiriu recentemente na biblioteca de documentos.

Visite a Biblioteca de Documentos

Ushma Mehta et al.
The Lancet. Infectious diseases, 7(11), 733-738 (2007-10-27)
The non-nucleoside reverse transcriptase inhibitors (NNRTIs) efavirenz and nevirapine are chemically distinct, but both may cause cutaneous hypersensitivity and hepatotoxicity. We reviewed the literature to assess the evidence for cross-reactivity between nevirapine and efavirenz. All papers, abstracts, or presentations, regardless
Nathan Ford et al.
AIDS (London, England), 27(7), 1135-1143 (2013-01-10)
The risk of adverse drug events associated with nevirapine (NVP) is suggested to be greater in pregnant women. We conducted a systematic review and meta-analysis of severe adverse events in HIV-positive women who initiated NVP while pregnant. We searched six
Ebrahim Bera et al.
South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 102(11 Pt 1), 855-859 (2012-11-03)
The package insert for nevirapine (NVP) cautions use in HIV-infected women (including pregnant women) with CD4 counts ≥250 cells/µl. However, recent studies showed that the CD4 count of pregnant women receiving antiretroviral therapy (ART) was not predictive of NVP toxicity.
Laura O Coster et al.
AIDS reviews, 14(2), 132-144 (2012-05-26)
Nevirapine was the first nonnucleoside reverse transcriptase inhibitor that was approved for treatment of HIV infection and quickly became an important component of HAART. As experience with this drug grew, potential toxicities and significant clinical benefits became apparent. With the
M Popovic et al.
Handbook of experimental pharmacology, (196)(196), 437-451 (2009-12-19)
Treatment of HIV-1 infections with nevirapine is associated with skin and liver toxicity. These two organ toxicities range from mild to severe, in rare cases resulting in life-threatening liver failure or toxic epidermal necrolysis. The study of the mechanistic steps
Exibir todos os documentos relacionados

Questions

Reviews

No rating value

Active Filters

Nossa equipe de cientistas tem experiência em todas as áreas de pesquisa, incluindo Life Sciences, ciência de materiais, síntese química, cromatografia, química analítica e muitas outras.

Entre em contato com a assistência técnica